Role of polymorphisms of folate-cycle enzymes in diabetic retinopathy progression in patients with type 2 diabetic mellitus
Keywords:diabetic retinopathy, type 2 diabetes mellitus, folate cycle, homocystein, MTHFR C677T, MTHFR A1298C, MTRA 2756G polymorphisms
UDC 617.735-02 :616.379-008.64-036.17:575.17
Background: Hyperhomocysteinemia is important in the development of endothelial dysfunction, a pathogenetic component of diabetic retinopathy (DR) in type 2 diabetes mellitus (DM2). The major cause of homocysteine accumulation is missing or dysfunctional enzymes and cofactors that are needed to perform homocystein metabolic processes. This is, for the most part, the deficiency of folate cycle enzymes determined by methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, and methionine synthase (MTR) A2756G polymorphisms.
Purpose: To assess the role of polymorphisms of folate cycle enzymes (MTHFR C677T, MTHFR A1298C, MTR A2756G) in DR progression in patients with DM2.
Material and Methods: The study included 83 DM2 patients (83 eyes) in whom DR met the criteria of non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) according to the Early Treatment of Diabetic Retinopathy Study (ETDRS). The control group was composed of 35 non-diabetics comparable to patients with respect to gender, age and body mass index. Real-time PCR was conducted on a Gene Amp® PCR System 7500 to determine polymorphisms. Plasma L-homocysteine levels were determined using an enzyme-linked immunosorbent assay (ELISA) microplate reader and Axis® Homocysteine Enzyme Immunoassay Kit (AXIS-SHIELD Diagnostics Ltd).
Conclusion: We found no association of rs1801133, rs1805087, and rs1801131, folate-cycle polymorphisms, with the development of DR in DM2, compared with non-diabetics. In NPDR patients having the minor homozygous GG genotype of MTR 2756А/G and/or the minor homozygous CC genotype of MTHFR 1298A/C, plasma L-homocysteine levels were significantly increased. This requires further elucidation of the role of hyperhomocysteinemia as a factor of DR progression or as a marker of the severity of tissue injury. The duration of DM2 is an important factor of DR progression in carriers of the most common CC and CT genotypes of rs1801133, AG genotype of rs1805087, and АА genotype of rs1801131.
Barrett E.J., Liu Z., Khamaisi M. et al. Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. The Journal of clinical endocrinology and metabolism, 2017,102(12), 4343–4410.
Shi C., Wang P., Airen S. et al. Nutritional and medical food therapies for diabetic retinopathy. Eye and vision (London, England), 2020, 7, 33.
Natrus L.V. A novel concept of differences in pathogenetic mechanism of diabetic retinopathy progression between type 2 diabetes mellitus patients differing in the PPAR? genotype. J.ophthalmol.(Ukraine).2020;5:36-42.
Kowluru R.A. Diabetic Retinopathy: Mitochondria Caught in a Muddle of Homocysteine. Journal of clinical medicine, 2020,9(9), 3019.
Kowluru R.A., Mohammad G., Sahajpal N. Faulty homocysteine recycling in diabetic retinopathy. Eye and vision (London, England), 2020,7, 4.
Malaguarnera G, Gagliano C, Giordano M, et al. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. Biomed Res Int. 2014; 2014:191497.
Koklesova L, Mazurakova A, Samec M, et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. The EPMA journal, 2021,12(4), 1–29. Advance online publication.
Raghubeer S, &Matsha TE. Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks. Nutrients, 2021, 13(12), 4562.
Tawfik A, Mohamed R, Elsherbiny N et al. Homocysteine: A Potential Biomarker for Diabetic Retinopathy. Journal of clinical medicine, 2019, 8(1), 121.
Maltsev D, Natrus L. The Effectiveness of Infliximab in Autism Spectrum Disorders Associated with Folate Cycle Genetic Deficiency. Psychiatry, psychotherapy and clinical psychology, 2020, Vol 11, (3). Р 581-592. DOI:10.34883/PI.2020.11.3.015
Maltsev D. Features of folate cycle disorders in children with ASD. Bangladesh Journal of Medical Science, 2020, 19(4), 737–742.
Niu W, Qi Y. An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. Diabetes Res Clin Pract. 2012, 95(1):110-8.
Xu WH, Zhuang Y, Han X, Yuan ZL. Methylenetetrahydrofolate reductase C677T polymorphism and diabetic retinopathy risk: a meta-analysis of the Chinese population. J Int Med Res. 2020;48(1):300060518816834.
Luo S, Wang F, Shi C, Wu Z. A Meta-Analysis of Association between Methylenetetrahydrofolate Reductase Gene (MTHFR) 677C/T Polymorphism and Diabetic Retinopathy. International Journal of Environmental Research and Public Health. 2016; 13(8):806.
Raza ST, Abbas S, Ahmed F, Fatima J, Zaidi ZH, Mahdi F. Association of MTHFR and PPAR?2 gene polymorphisms in relation to type 2 diabetes mellitus cases among north Indian population. Gene. 2012, 15;511(2):375-9.
Zhong JH, Rodr?guez AC, Yang NN, Li LQ. Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus. PLoS One. 2013 Sep 4;8(9):e74521.
How to Cite
Copyright (c) 2022 Сергей Александрович Рыков, Юлия Валерьевна Прокопенко, Лариса Валентиновна Натрус, Юлия Панченко
This work is licensed under a Creative Commons Attribution 4.0 International License.